Stockscreener 앱 받기
2.95
7.52%
-0.24
시간 외 거래:
2.92
-0.03
-1.02%
전일 마감가:
$3.19
열려 있는:
$3.22
하루 거래량:
106.90K
Relative Volume:
1.54
시가총액:
$10.66M
수익:
-
순이익/손실:
$-55.84M
주가수익비율:
-0.1677
EPS:
-17.5951
순현금흐름:
$-49.61M
1주 성능:
-52.42%
1개월 성능:
-68.35%
6개월 성능:
-76.08%
1년 성능:
+495.36%
1일 변동 폭
$2.91
$3.29
1주일 범위
$2.83
$6.96
52주 변동 폭
$0.39
$15.74
Nextcure Inc Stock (NXTC) Company Profile
명칭
Nextcure Inc
전화
240-399-4900
주소
9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE, MD
Compare NXTC vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NXTC
Nextcure Inc
|
2.95 | 11.52M | 0 | -55.84M | -49.61M | -17.60 |
VRTX
Vertex Pharmaceuticals Inc
|
446.83 | 112.12B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
635.45 | 65.92B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
891.32 | 52.38B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.05 | 40.54B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
149.23 | 33.10B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nextcure Inc Stock (NXTC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-07 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2022-11-04 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2022-03-01 | 개시 | Ladenburg Thalmann | Buy |
| 2021-03-05 | 업그레이드 | Truist | Hold → Buy |
| 2021-01-15 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2020-07-16 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2020-07-13 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2020-07-13 | 다운그레이드 | SunTrust | Buy → Hold |
| 2020-06-01 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2020-06-01 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2020-05-26 | 개시 | JMP Securities | Mkt Outperform |
| 2020-03-24 | 개시 | The Benchmark Company | Buy |
| 2020-03-02 | 개시 | ROTH Capital | Buy |
| 2020-01-13 | 개시 | SunTrust | Buy |
| 2019-12-05 | 개시 | Needham | Buy |
| 2019-11-26 | 개시 | BTIG Research | Buy |
| 2019-07-09 | 개시 | BofA/Merrill | Buy |
| 2019-06-03 | 개시 | Morgan Stanley | Overweight |
| 2019-06-03 | 개시 | Piper Jaffray | Overweight |
모두보기
Nextcure Inc 주식(NXTC)의 최신 뉴스
What's going on with NextCure stock Wednesday? - MSN
NXTC Announces Replay Available for Virtual KOL Event Discussing ASCO 2026 Dose Escalation Data from Phase 1 Trial of SIM0505 for Gynecologic Cancers - The Manila Times
Cancer experts discuss SIM0505 trial data in on-demand replay - Stock Titan
What's Going On With NextCure Stock Wednesday? - Benzinga
NextCure, Inc. (NXTC) Discusses Preliminary Phase I Data for SIM0505 in Platinum-Resistant Ovarian Cancer and Uterine Serous CarcinomaSlideshow (NASDAQ:NXTC) 2026-06-02 - Seeking Alpha
Lucid Capital Maintains NextCure(NXTC.US) With Buy Rating, Maintains Target Price $25 - Moomoo
NextCure Reports 55% Response Rate in Phase 1 SIM0505 Trial for Gynecologic Cancers at ASCO 2026 - Minichart
NextCure Reports Positive SIM0505 Phase 1 Gynecologic Cancer Data - TipRanks
NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026 - The Manila Times
NextCure presents SIM0505 Phase 1 data: 55% ORR in gynecologic cancers; cash runway into Q1 2027 - TradingView
NextCure reports 55% response rate for SIM0505 in gynecologic cancers - Investing.com
Strong SIM0505 Phase 1 gynecologic cancer data for NextCure (Nasdaq: NXTC) - Stock Titan
Experimental ovarian and uterine cancer drug shows 55% response rate - Stock Titan
NextCure Inc. (NXTC) Surges 5.44% as Shares Test Key ResistanceGap Up Stocks - The Legal Advocate
NXTC - Finviz
NextCure (NXTC) Plunges Over 22% as Selling Pressure IntensifiesWedge Breakout - The Legal Advocate
NextCure Inc. (NXTC) Q1 2026 Earnings: EPS Beat Amid No Revenue and Steep Stock DeclineEarnings Sentiment Score - The Legal Advocate
NextCure Inc. (NXTC) Gains 5.75% as Biotech Stock Tests Resistance Near $10.71Bollinger Band - Newser
NextCure stock (US65343E1082): biotech shares in focus after China licensing deal for SIM0505 - AD HOC NEWS
NextCure (NXTC) Q1 2026 Earnings: $-1.87 EPS Surges Past $-2.15 EstimatesSocial Buy Zones - Newser
NXTC NextCure earnings beat estimates by 67 percent yet shares retreat despite EPS outperformanceSubscription Growth Report - newsline.com
NextCure stock (US65343E1082): biotech shares react to recent strategic update and Nasdaq trading mo - AD HOC NEWS
SilverArc and Devesh Gandhi report 176,057 shares in NextCure (NXTC) - Stock Titan
TradingKey - TradingKey
Lucid Capital Markets initiates NextCure stock with buy on ADC pipeline By Investing.com - Investing.com South Africa
Lucid Capital Markets initiates NextCure stock with buy on ADC pipeline - Investing.com
Lucid Capital Initiates NextCure(NXTC.US) With Buy Rating, Announces Target Price $25 - Moomoo
NXTC (NextCure) earnings beat estimates by 67 percent, yet shares retreat despite EPS outperformance.Attention Driven Stocks - Newser
How NextCure (NXTC) maintains its competitive edge | Q4 2025: Profit Exceeds ViewsRevenue Inflection Point - Newser
NextCure | 10-Q: Quarterly report - Moomoo
NextCure 1Q Loss/Shr $1.87 >NXTC - Moomoo
NextCure | 10-Q: Q1 2026 Earnings Report - Moomoo
NextCure (NASDAQ: NXTC) narrows loss but warns on going-concern and funding needs - Stock Titan
NextCure | 8-K: NextCure Provides Business Update and Reports First Quarter 2026 Financial Results - Moomoo
FDA Fast Track and narrower loss mark Q1 2026 for NextCure (NASDAQ: NXTC) - Stock Titan
NextCure maps June cancer data, says cash lasts into 2027 - Stock Titan
NextCure Provides Business Update and Reports First Quarter 2026 Financial Results - Weekly Voice
Simcere entities disclose 9.4% stake in NextCure (NXTC) - Stock Titan
NextCure initiates dose optimization study for ovarian cancer drug - Investing.com
NextCure initiates dose optimization study for ovarian cancer drug By Investing.com - Investing.com Nigeria
Biotechnology company NextCure Inc. announced it is accelerating the progress of its R&D projects by expanding its clinical research center network to Canada and Europe. - Bitget
NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers - The Manila Times
NextCure moves ovarian cancer drug into dose testing before ASCO - Stock Titan
NextCure Inc expected to post a loss of $1.81 a shareEarnings Preview - TradingView
What capacity utilization NextCure (NXTC)? (-2.47%) 2026-04-27Crowd Consensus Signals - Newser
NextCure (NXTC) Stock Rejected Order (Smart Money Exits) 2026-04-24Top Analyst Picks - Newser
NextCure (NASDAQ: NXTC) plans 2026 meeting, auditor, pay and equity plan votes - Stock Titan
Nextcure Inc (NXTC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.13%
3.22%
자본화:
|
볼륨(24시간):